科笛-B(02487.HK)皮膚表皮麻醉乳膏劑III期臨床完成所有受試者出組
科笛-B(02487.HK)公布,CU-30101,一種用於皮膚表皮手術的局部利多卡因丁卡因複合表皮麻醉乳膏劑,其III期臨床試驗完成所有受試者出組。
公司指出,由於其成份的獨特藥代動力學特性,CU-30101的利多卡因和丁卡因組合配方可產生快速且持久的麻醉效果。利多卡因較丁卡因彌散更快且彌散範圍更廣,而丁卡因是一種長效氨基酸酯類局麻藥,較利多卡因更親脂,可在表皮角質層中濃縮。麻醉成分的全身吸收亦受到表皮乳膏配方的限制。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.